30 March 2011 in Arthritis Care & Research
Click on the article title to read more.
28 January 2011 in Arthritis & Rheumatism
27 February 2007 in Arthritis & Rheumatism
19 December 2011 in Arthritis & Rheumatism
FAfor the Childhood Arthritis and Rheumatology Research Alliance
for the Childhood Arthritis and Rheumatology Research Alliance
+17
Objective: To determine whether aggressive treatment initiated early in the course of rheumatoid factor (RF)–positive or RF‐negative polyarticular juvenile idiopathic arthritis (JIA) can induce clinical inactive disease within 6 months.Methods: Between May 2007 and October 2010, a multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of 2 aggressive treatments was conducted in 85 children ages 2–16 years with polyarticular JIA of <12 months' duration. Patients received either methotrexate (MTX) 0.5 mg/kg/week (maximum 40 mg) subcutaneously, etanercept 0.8 mg/kg/week (maximum 50 mg), and prednisolone 0.5 mg/kg/day (maximum 60 mg) tapered to 0 by 17 weeks (arm 1), or MTX (same dosage as arm 1), etanercept placebo, and prednisolone placebo (arm 2). The primary outcome measure was clinical inactive disease at 6 months. An exploratory phase determined the rate of clinical remission on medication (6 months of continuous clinical inactive disease) at 12 months.Results: By 6 months, clinical inactive disease had been achieved in 17 (40%) of 42 patients in arm 1 and 10 (23%) of 43 patients in arm 2 (χ2 = 2.91, P = 0.088). After 12 months, clinical remission on medication was achieved in 9 patients in arm 1 and 3 patients in arm 2 (P = 0.053). There were no significant interarm differences in adverse events.Conclusion: Although this study did not meet its primary end point, early aggressive therapy in this cohort of children with recent‐onset polyarticular JIA resulted in clinical inactive disease by 6 months and clinical remission on medication within 12 months of treatment in substantial proportions of patients in both arms.
25 April 2008 in Arthritis & Rheumatism
PGPediatric Rheumatology Collaborative Study Group
Pediatric Rheumatology Collaborative Study Group
+3
30 January 2012 in Arthritis Care & Research
OAon behalf of the Juvenile Idiopathic Arthritis Disease‐specific Research Committee of the Childhood Arthritis Rheumatology and Research Alliance
on behalf of the Juvenile Idiopathic Arthritis Disease‐specific Research Committee of the Childhood Arthritis Rheumatology and Research Alliance
+11
Objective: There is wide variation in therapeutic approaches to systemic juvenile idiopathic arthritis (JIA) among North American rheumatologists. Understanding the comparative effectiveness of the diverse therapeutic options available for treatment of systemic JIA can result in better health outcomes. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed consensus treatment plans and standardized assessment schedules for use in clinical practice to facilitate such studies.Methods: Case‐based surveys were administered to CARRA members to identify prevailing treatments for new‐onset systemic JIA. A 2‐day consensus conference in April 2010 employed modified nominal group technique to formulate preliminary treatment plans and determine important data elements for collection. Followup surveys were employed to refine the plans and assess clinical acceptability.Results: The initial case‐based survey identified significant variability among current treatment approaches for new‐onset systemic JIA, underscoring the utility of standardized plans to evaluate comparative effectiveness. We developed 4 consensus treatment plans for the first 9 months of therapy, as well as case definitions and clinical and laboratory monitoring schedules. The 4 treatment regimens included glucocorticoids only, or therapy with methotrexate, anakinra, or tocilizumab, with or without glucocorticoids. This approach was approved by >78% of the CARRA membership.Conclusion: Four standardized treatment plans were developed for new‐onset systemic JIA. Coupled with data collection at defined intervals, use of these treatment plans will create the opportunity to evaluate comparative effectiveness in an observational setting to optimize initial management of systemic JIA.